Novel Oral Poliovirus Vaccine 2 Safety Evaluation during Nationwide Supplemental Immunization Activity, Uganda, 2022

Emerg Infect Dis. 2024 Apr;30(4):775-778. doi: 10.3201/eid3004.231361.

Abstract

Given its enhanced genetic stability, novel oral poliovirus vaccine type 2 was deployed for type 2 poliovirus outbreak responses under World Health Organization Emergency Use Listing. We evaluated the safety profile of this vaccine. No safety signals were identified using a multipronged approach of passive and active surveillance.

Keywords: Uganda; poliovirus; vaccine safety; vaccines; viruses.

MeSH terms

  • Immunization
  • Poliovirus Vaccine, Oral / adverse effects
  • Poliovirus* / genetics
  • Uganda / epidemiology
  • Vaccination / adverse effects

Substances

  • Poliovirus Vaccine, Oral